DOH: 14,907 dengue cases recorded as of February 14
MANILA, Philippines — The Department of Health (DOH) has recorded 14,907 dengue cases as of Feb. 14, which is 70 percent lower compared to the same period last year.
The decline reflects stronger prevention measures and early consultation, as well as surveillance and clinical management, Health Undersecretary Gloria Balboa said yesterday.
At the Philippine Medical Association (PMA)’s “End Dengue Coalition” event in Quezon City, Balboa reminded the public to remain vigilant as dengue cases could rise.
Dengue is “all-year round, but has its peak cycles that include the July to October period,” said Eric Tayag, a former health undersecretary and part of the PMA ad hoc committee on dengue advocacy.
Based on DOH data, 45 percent of dengue cases in 2025 were recorded from July to October, Tayag noted.
Lulu Bravo, another member of the ad hoc committee, stressed the need for new interventions, such as vaccination, to prevent dengue.
After the Dengvaxia vaccine controversy in 2015, the country still has no widely available dengue vaccine approved by the Food and Drug Administration (FDA).
Japan-based Takeda Pharmaceuticals’ second-generation dengue vaccine Qdenga, despite compliance with requirements set by the FDA, remains under review.
DOH: 14,907 dengue cases recorded as of February 14
Rhodina
MANILA, Philippines — The Department of Health (DOH) has recorded 14,907 dengue cases as of Feb. 14, which is 70 percent lower compared to the same period last year.
The decline reflects stronger prevention measures and early consultation, as well as surveillance and clinical management, Health Undersecretary Gloria Balboa said yesterday.
At the Philippine Medical Association (PMA)’s “End Dengue Coalition” event in Quezon City, Balboa reminded the public to remain vigilant as dengue cases could rise.
Dengue is “all-year round, but has its peak cycles that include the July to October period,” said Eric Tayag, a former health undersecretary and part of the PMA ad hoc committee on dengue advocacy.
Based on DOH data, 45 percent of dengue cases in 2025 were recorded from July to October, Tayag noted.
Lulu Bravo, another member of the ad hoc committee, stressed the need for new interventions, such as vaccination, to prevent dengue.
After the Dengvaxia vaccine controversy in 2015, the country still has no widely available dengue vaccine approved by the Food and Drug Administration (FDA).
Japan-based Takeda Pharmaceuticals’ second-generation dengue vaccine Qdenga, despite compliance with requirements set by the FDA, remains under review.
- Latest
- Trending
